Proprietary AI analyst is now available

Cyclezyme Valuation Multiples

Discover revenue and EBITDA valuation multiples for Cyclezyme and similar public comparables like Australian Silica Quartz, EcoRub, OrganoClick, Trinseo and more.

Cyclezyme Overview

About Cyclezyme

Cyclezyme AB is a Sweden-based company that has developed an enzymatic platform focused on producing enzymes for green biochemical processes. This platform utilizes biotechnological methods to identify and improve enzymes capable of converting e.g. PET-based plastic materials for new building blocks. The company enables careful experiments and analyses of the behavior of different enzymes in the breakdown of e.g. PET material. The company refines its enzymes and also optimizes the processes for plastic recycling by combining experimental data with data analysis.


Founded

N/A

HQ

Sweden

Employees

N/A

Sectors

Financials (FY)

Revenue: $90K
EBITDA: ($158K)

EV

$4M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Cyclezyme Financials

Cyclezyme reported last fiscal year revenue of $90K and negative EBITDA of ($158K).

In the same fiscal year, Cyclezyme generated $266K in gross profit, ($158K) in EBITDA losses, and had net loss of ($168K).


Cyclezyme P&L

In the most recent fiscal year, Cyclezyme reported revenue of $90K and EBITDA of ($158K).

Cyclezyme is unprofitable as of last fiscal year, with gross margin of 297%, EBITDA margin of (177%), and net margin of (188%).

See analyst estimates for Cyclezyme
Last FY202320242025202620272028
Revenue$90K--$90K
Gross Profit$266K$144K$150K$266K
Gross Margin297%--297%
EBITDA($158K)($159K)($217K)($158K)
EBITDA Margin(177%)--(177%)
EBIT Margin(183%)--(183%)
Net Profit($168K)($161K)($227K)($168K)
Net Margin(188%)--(188%)

Financial data powered by Morningstar, Inc.

Cyclezyme Stock Performance

Cyclezyme has current market cap of $5M, and enterprise value of $4M.

Market Cap Evolution


Cyclezyme's stock price is $1.74.

Cyclezyme share price increased by 9.3% in the last 30 days, and decreased by 4.4% in the last year.

Cyclezyme has an EPS (earnings per share) of $-0.06.

See more trading valuation data for Cyclezyme
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$4M$5M-5.8%9.3%24.5%-4.4%$-0.06

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Cyclezyme Valuation Multiples

Cyclezyme trades at 48.5x EV/Revenue multiple, and (27.5x) EV/EBITDA.

See NTM and 2027E valuation multiples for Cyclezyme

Cyclezyme Financial Valuation Multiples

As of June 5, 2026, Cyclezyme has market cap of $5M and EV of $4M.

Cyclezyme has a P/E ratio of (26.8x).

Last FY202320242025202620272028
EV/Revenue48.5x--48.5x
EV/EBITDA(27.5x)(27.4x)(20.0x)(27.5x)
EV/EBIT(26.5x)(27.0x)(19.1x)(26.5x)
EV/Gross Profit16.3x30.2x29.1x16.3x
P/E(26.8x)(27.9x)(19.9x)(26.8x)
EV/FCF(10.0x)(12.3x)(11.4x)(10.0x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Cyclezyme Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Cyclezyme Margins & Growth Rates

In the most recent fiscal year, Cyclezyme reported gross margin of 297%, EBITDA margin of (177%), and net margin of (188%).

See estimated margins and future growth rates for Cyclezyme

Cyclezyme Margins

Last FY2025202720282029
Gross Margin297%297%
EBITDA Margin(177%)(177%)
EBIT Margin(183%)(183%)
Net Margin(188%)(188%)
FCF Margin(484%)(484%)

Cyclezyme Growth Rates

23/2424/2526/2727/2828/29
Gross Profit Growth4%78%
EBITDA Growth37%(27%)
EBIT Growth42%(28%)
Net Profit Growth41%(26%)
FCF Growth7%14%

Data powered by FactSet, Inc. and Morningstar, Inc.

Cyclezyme Operational KPIs

Access forward-looking KPIs for Cyclezyme
Last FY2025202620272028
Opex to Revenue481%481%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Cyclezyme Competitors

Cyclezyme competitors include Australian Silica Quartz, EcoRub, OrganoClick, Trinseo, Vystar, POLYDUCT Plastic, Svenska Aerogel, XP Chemistries, Sansuy Industria and Eko Export.

Most Cyclezyme public comparables operate across Chemicals.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Australian Silica Quartz----
EcoRub3.4x-(6.8x)-
OrganoClick1.2x-(9.7x)-
Trinseo-0.9x-16.8x
Vystar----
POLYDUCT Plastic0.2x-1.9x-
Svenska Aerogel10.6x-(2.1x)-
XP Chemistries84.1x14.3x(4.5x)(4.7x)

This data is available for Pro users. Sign up to see all Cyclezyme competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Cyclezyme

Where is Cyclezyme headquartered?Cyclezyme is headquartered in Sweden.
Is Cyclezyme publicly listed?Yes, Cyclezyme is a public company listed on Nasdaq Stockholm.
What is the stock symbol of Cyclezyme?Cyclezyme trades under CYCLE ticker.
When did Cyclezyme go public?Cyclezyme went public in 2023.
Who are competitors of Cyclezyme?Cyclezyme main competitors include Australian Silica Quartz, EcoRub, OrganoClick, Trinseo, Vystar, POLYDUCT Plastic, Svenska Aerogel, XP Chemistries, Sansuy Industria, Eko Export.
What is the current market cap of Cyclezyme?Cyclezyme's current market cap is $5M.
What is the current revenue of Cyclezyme?Cyclezyme's last fiscal year revenue is $90K.
What is the current EV/Revenue multiple of Cyclezyme?Current revenue multiple of Cyclezyme is 48.5x.
Is Cyclezyme profitable?No, Cyclezyme is not profitable.
How many companies Cyclezyme has acquired to date?Cyclezyme hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Cyclezyme has invested to date?Cyclezyme hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Cyclezyme

Lists including Cyclezyme

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial